苑东生物子公司硕德药业通过美国FDA现场检查

Core Viewpoint - The company, Yuandong Biotech (688513.SH), announced that its wholly-owned subsidiary, Chengdu Shode Pharmaceutical Co., Ltd., successfully passed FDA inspections for the production of Naloxone nasal spray with zero deficiencies [1] Group 1 - The inspections conducted by the FDA included Current Good Manufacturing Practice (cGMP) and Bioresearch Monitoring (BIMO) [1] - The inspections took place from May 6 to May 9 and May 16 to May 22, 2025 [1] - The company received two Establishment Inspection Reports (EIR) from the FDA confirming the successful inspections [1]